1st Aug 2008 14:53
Total Voting Rights
Basingstoke, UK and Philadelphia, US - August 01, 2008 - Shire Limited , the global specialty biopharmaceutical company, in accordance with DTR 5.6.1 of the FSA's Disclosure and Transparency Rules, notifies the market of the following:
At close of business on 31 July 2008, Shire Limited's issued voting share capital consisted of 559,900,391 ordinary shares with a nominal value of 5 pence. Each ordinary share carries one voting right. Shire Limited does not hold any shares in Treasury.
The above figure (559,900,391) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Shire Limited under the FSA's Disclosure and Transparency Rules.
T MayCompany Secretary
For further information please contact:
Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Eric Rojas (North America) +1 484 595 8252 Notes to editorsSHIRE LIMITED
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.
vendorRelated Shares:
Shire